Literature DB >> 8949394

In vivo treatment with interleukin 2 reduces parasitemia and restores IFN-gamma gene expression and T-cell proliferation during acute murine malaria.

B Lucas1, L H Kasper, K Smith, A Haque.   

Abstract

In this study, we describe the functional alterations in the host immune system that occur following acute infection with Plasmodium yoelii. Further, we have addressed the question whether the transient condition of altered immune responsiveness can be restored by a cytokine therapy. The lymphoproliferative response towards concanavalin A (Con A) or to cross-linked anti-CD3 mAb was significantly diminished in acutely infected mice compared to immune and normal animals. This condition was associated with poor production of IL-2. In vivo treatment with recombinant IL-2 (rIL-2) resulted in marked diminution of parasitemia (from 24% +/- 6% to 8% +/- 3%) in mice during the acute phase of infection. Despite this diminution in parasitemia, 70% of the IL-2 treated mice died by day 17 post infection. In vivo treatment with rIL-2 led to a partial but significant restoration in lymphoproliferative response to TCR-mediated (cross-linked anti-CD3 mAb) or to Con A-induced stimulation in acutely infected mice. The transcripts for IL-4, IL-5, GM-CSF, and TNF-alpha were expressed in the splenocytes from acutely infected mice not treated with rIL-2. mRNAs for IL-2, IFN-gamma, IL-6, IL-10 which were not detected in acutely infected mice could be reversed by administration of rIL-2 in vivo. We suggest that some of the hyporesponsive T-cells in the acute phase of infection have the potential to be reversed, and this reversal is manifested also at the level of cytokine gene expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8949394

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  7 in total

1.  Antigen-presenting cell function during Plasmodium yoelii infection.

Authors:  James Luyendyk; O Renee Olivas; Lisa A Ginger; Anne C Avery
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 2.  Cytokines in the pathogenesis of and protection against malaria.

Authors:  Iñigo Angulo; Manuel Fresno
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

3.  Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection.

Authors:  G Wunderlich; I C Moura; H A del Portillo
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle.

Authors:  I Gentschev; I Glaser; W Goebel; D J McKeever; A Musoke; V T Heussler
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Cerebral malaria in mice: interleukin-2 treatment induces accumulation of gammadelta T cells in the brain and alters resistant mice to susceptible-like phenotype.

Authors:  A Haque; H Echchannaoui; R Seguin; J Schwartzman; L H Kasper; S Haque
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection.

Authors:  A Haque; N Rachinel; M R Quddus; S Haque; L H Kasper; E Usherwood
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

7.  Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites.

Authors:  Leanne M Low; Aloysious Ssemaganda; Xue Q Liu; Mei-Fong Ho; Victoria Ozberk; James Fink; Lana Sundac; Kylie Alcorn; Amy Morrison; Kevin O'Callaghan; John Gerrard; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2018-12-19       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.